Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLisuride maleate is a dopamine receptor agonist and anti-Parkinson's agent. Displays high affinity for D2, D3 and D4 receptors along with 5-HT1A. Exhibits some 5-HT2B receptor antagonist properties. Decreases prolactin release; reduces inflammatory mediators such as TNF-α and IL6. Exhibits anticonvulsive effects. Acts similar to bromocriptine (Cat. No. 0427).
分子量 | 454.52 |
公式 | C20H26N4O.C4H4O4 |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 19875-60-6 |
PubChem ID | 5282421 |
InChI Key | CVQFAMQDTWVJSV-BAXNFHPCSA-N |
Smiles | OC(/C=C\C(O)=O)=O.[H][C@@]1(C2)C(C3=C4C2=CNC4=CC=C3)=C[C@H](NC(N(CC)CC)=O)CN1C |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 44.66 | 100 |
以下数据基于产品分子量 454.52。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.2 mL | 11 mL | 22 mL |
5 mM | 0.44 mL | 2.2 mL | 4.4 mL |
10 mM | 0.22 mL | 1.1 mL | 2.2 mL |
50 mM | 0.04 mL | 0.22 mL | 0.44 mL |
参考文献是支持产品生物活性的出版物。
Hofmann et al (2006) Lisuride, a DA receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis Clin.Neuropharmacol. 29 80 PMID: 16614540
Zweckberger et al (2010) Anticonvulsive effects of the DA agonist lisuride maleate after experimental traumatic brain injury. Neurosci.Lett. 470 150 PMID: 20056133
Woitalla et al (2004) Transdermal lisuride delivery in the treatment of Parkinson's disease. J.Neural Transm. 68 89
If you know of a relevant reference for Lisuride maleate, please let us know.
关键词: Lisuride maleate, Lisuride maleate supplier, antiparkinsonian, drug, anti-Parkinson's, disease, dopaminergic, agonists, dopamine, receptor, agonist, DA, Non-selective, Dopamine, 5-HT, 4052, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Lisuride maleate 的部分引用包括:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacol 175 PMID: 32088264
Chan et al (2018) Coalescing beneficial host and deleterious antiparasitic actions as an antischistosomal strategy. Elife 7 PMID: 30059006
McCorvy et al (2018) Structural determinants of 5-HT2B receptor activation and biased agonism. Nat Struct Mol Biol 25 787 PMID: 30127358
Tomasz et al (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 26 1032-1041 PMID: 37280397
您是否知道使用了 Tocris Lisuride maleate 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Lisuride maleate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.